by Co-Diagnostics | Jul 27, 2017 | News Release
SALT LAKE CITY, July 27, 2017 (GLOBE NEWSWIRE) — Co-Diagnostics, Inc. (NASDAQ:CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, has completed principle... by Co-Diagnostics | Jul 25, 2017 | News Release
SANDY, Utah–(BUSINESS WIRE)–Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, officially announced today the recent incorporation of CoSara Diagnostics, Pvt., Ltd., a... by Co-Diagnostics | Jul 17, 2017 | News Release
Sandy, UT – July 17, 2017 – Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, has completed its initial public offering and started... by Co-Diagnostics | Jul 12, 2017 | News Release
Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests, announced today that its initial public offering of 1,178,532 shares of... 